Monopar Therapeutics Inc (MNPR)

$99.39 +2.18 (2.24%)
Market Cap 613.24M
Revenue (ttm) 0.00
Net Income (ttm) -15.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 117,900
Avg Vol 48,080
Day's Range N/A - N/A
Shares Out 6.17M
Stochastic %K 96%
Beta 1.42
Analysts Strong Sell
Price Target $99.11

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology
Sector: Healthcare
Phone: 847 388 0349
Address:
1000 Skokie Boulevard, Suite 350, Wilmette, United States
Bullbear1010101
Bullbear1010101 Oct. 4 at 12:33 PM
$MNPR Seems top soon. bubble almost
0 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 3 at 9:58 PM
$MNPR If MNPR csn do it, so can $CYCN 💪🏽
0 · Reply
WallStVisions
WallStVisions Oct. 3 at 1:06 PM
If GIPR becomes the next REIT-crypto hybrid play, the re rate will be violent. Add in a micro float, real tenants, and a book value that’s completely ignored this could be the next legendary rerate ticker. Eyes on this before it headlines. $MNPR $THMO $LGVN $HOOK $PEV
0 · Reply
AtlasFrontier
AtlasFrontier Oct. 3 at 3:43 AM
I found a stock that is about to absolutely explode Tomorrow. Check out GIPR 🚨🚀 GIPR 🚀🔥 🔹 Early lease extension w/ Best Buy thru 2032 + rent bump 6.5% 📈 🔹 Revenue up ~28% YoY to $9.7M 💰 🔹 Exploring strategic alternatives – sale/merger/recap possibilities 🧐 🔹 High occupancy & investment-grade tenants keep cash flowing 🏢 $AREC $MNPR $MYND $MFH
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 2 at 2:37 PM
$RADX $MNPR and $RADX are completely different companies with different value drivers. one is not an indicator of what the other can do. they're both good opportunities imho, but no need to compare.
3 · Reply
DARKP00L
DARKP00L Oct. 2 at 2:33 PM
$MNPR 10:10 on Oct. 02 2025 Monopar Therapeutics shares are trading higher after Oppenheimer raised its price target on the stock from $77 to $115. #tradeideas
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 2 at 2:23 PM
$MNPR
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 1:59 PM
Oppenheimer updates rating for Monopar Therapeutics ( $MNPR ) to Outperform, target set at 77 → 115.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 1 at 5:41 PM
$RADX $85 now… wow $MNPR
1 · Reply
Stanfordfund
Stanfordfund Sep. 30 at 8:59 PM
$MNPR I'll be riding this one off into the sunset! Diamond Hands
0 · Reply
Latest News on MNPR
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Sep 23, 2025, 11:08 PM EDT - 10 days ago

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Sep 23, 2025, 11:07 PM EDT - 10 days ago

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Sep 14, 2025, 8:00 AM EDT - 20 days ago

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Sep 4, 2025, 10:29 AM EDT - 4 weeks ago

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Aug 12, 2025, 8:00 AM EDT - 7 weeks ago

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Jun 11, 2025, 7:00 AM EDT - 4 months ago

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 3, 2025, 7:00 AM EDT - 4 months ago

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025, 8:00 AM EDT - 5 months ago

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025, 2:30 AM EDT - 5 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Apr 29, 2025, 8:00 AM EDT - 5 months ago

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Jan 23, 2025, 1:10 PM EST - 9 months ago

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Dec 23, 2024, 2:23 PM EST - 10 months ago

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 20, 2024, 9:00 AM EST - 10 months ago

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Dec 5, 2024, 4:21 PM EST - 10 months ago

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 10 months ago

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Nov 25, 2024, 7:53 PM EST - 11 months ago

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Nov 8, 2024, 8:00 AM EST - 11 months ago

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Oct 30, 2024, 1:42 PM EDT - 1 year ago

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024, 9:15 PM EDT - 1 year ago

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 4:00 PM EDT - 1 year ago

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Oct 28, 2024, 1:29 PM EDT - 1 year ago

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Oct 24, 2024, 1:18 PM EDT - 1 year ago

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

AZN

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Aug 21, 2024, 8:00 AM EDT - 1 year ago

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Monopar and NorthStar Amend & Extend Collaboration

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Monopar Announces CFO Succession

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

May 9, 2024, 7:00 AM EDT - 1 year ago

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Mar 5, 2024, 7:00 AM EST - 1 year ago

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Feb 27, 2024, 7:00 AM EST - 1 year ago

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Feb 20, 2024, 8:00 AM EST - 1 year ago

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Nov 9, 2023, 7:00 AM EST - 2 years ago

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Oct 10, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Jun 21, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

Jun 14, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

May 11, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

Bullbear1010101
Bullbear1010101 Oct. 4 at 12:33 PM
$MNPR Seems top soon. bubble almost
0 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 3 at 9:58 PM
$MNPR If MNPR csn do it, so can $CYCN 💪🏽
0 · Reply
WallStVisions
WallStVisions Oct. 3 at 1:06 PM
If GIPR becomes the next REIT-crypto hybrid play, the re rate will be violent. Add in a micro float, real tenants, and a book value that’s completely ignored this could be the next legendary rerate ticker. Eyes on this before it headlines. $MNPR $THMO $LGVN $HOOK $PEV
0 · Reply
AtlasFrontier
AtlasFrontier Oct. 3 at 3:43 AM
I found a stock that is about to absolutely explode Tomorrow. Check out GIPR 🚨🚀 GIPR 🚀🔥 🔹 Early lease extension w/ Best Buy thru 2032 + rent bump 6.5% 📈 🔹 Revenue up ~28% YoY to $9.7M 💰 🔹 Exploring strategic alternatives – sale/merger/recap possibilities 🧐 🔹 High occupancy & investment-grade tenants keep cash flowing 🏢 $AREC $MNPR $MYND $MFH
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 2 at 2:37 PM
$RADX $MNPR and $RADX are completely different companies with different value drivers. one is not an indicator of what the other can do. they're both good opportunities imho, but no need to compare.
3 · Reply
DARKP00L
DARKP00L Oct. 2 at 2:33 PM
$MNPR 10:10 on Oct. 02 2025 Monopar Therapeutics shares are trading higher after Oppenheimer raised its price target on the stock from $77 to $115. #tradeideas
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 2 at 2:23 PM
$MNPR
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 1:59 PM
Oppenheimer updates rating for Monopar Therapeutics ( $MNPR ) to Outperform, target set at 77 → 115.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 1 at 5:41 PM
$RADX $85 now… wow $MNPR
1 · Reply
Stanfordfund
Stanfordfund Sep. 30 at 8:59 PM
$MNPR I'll be riding this one off into the sunset! Diamond Hands
0 · Reply
IN0V8
IN0V8 Sep. 29 at 6:26 PM
$MNPR Watch H.C. Wainwright raises target price to $105 from $70
0 · Reply
JarvisFlow
JarvisFlow Sep. 29 at 2:09 PM
HC Wainwright & Co. has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 105.
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 28 at 1:48 AM
October will be a big month Data Rad101 Rad202 Rad204 $RADX $LNTH $MNPR https://youtu.be/df1JoFcU7gA?si=mOdwgLipgYWHFGmr
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 27 at 8:17 PM
$RADX Radiopharm Theranostics (Nasdaq: RADX) ———-RAD202—— October Data — $7.5 to $15 billion yearly market opportunity per ChatGPT llm. 100,000 to 200,000 patients globally and $75,000 price tag. Nsclc, head & neck and melanoma https://www.oncidiumfoundation.org/wp-content/uploads/2025/04/177Lu-anti-PD-L1-sdAb.pdf Lantheus bought more at $12 in first quarter. Leader in Radiopharma field. Insiders invested heavily past 24 mos $PYXS $IMNM $MNPR
3 · Reply
CarolinesCurrency
CarolinesCurrency Sep. 27 at 2:59 AM
Watch IVDA the next 20 bagger in small caps. Weapon detection. Facial recognition. Real-time AI threat surveillance. IVDA isn’t theoretical they’re already deploying tech. And the market hasn’t noticed. Yet. Still sitting at dead lows with a float that can move. $VERU $ACXP $HILS $SDIG $MNPR .......
1 · Reply
thefastfreddy
thefastfreddy Sep. 27 at 12:03 AM
Watch IVDA Everyone's chasing what already ran. Meanwhile, is literally combining AI, robotics, and defense infrastructure in one microcap and it’s trading at dead lows. The next security contract or PR could set this off. $AKTS $MNPR $CVKD $SYTA $FRGT
1 · Reply
CryptoSenderX
CryptoSenderX Sep. 25 at 7:32 PM
$TIVC ultra bullish conference!!! Hidden Gem 💎 This will run hard like $MNPR I $SPRC I $VKTX I 🪐
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 4:53 PM
Piper Sandler updates rating for Monopar Therapeutics ( $MNPR ) to Overweight, target set at 76 → 95.
0 · Reply
Quantumup
Quantumup Sep. 25 at 1:10 PM
Piper Sandler raised the PT on $MNPR to $95 from $76, reiterated at an Overweight and said,Two Recent Datapoints De-Risk The Regulatory Hurdle for ALXN1840 [ $AZN ] Piper Sandler added, This morning, MNPR highlighted a new analysis of the Phase 2 ALXN1840-WD-204 study that disputes the earlier conclusion regarding ALXN1840's lack of effect on copper excretion in patients with Wilson Disease. By considering all pathways of copper loss, beyond just fecal and urinary excretion, this analysis demonstrates that ALXN1840 effectively promotes copper excretion. Herein, we also compare and contrast the recent accelerated approval of Stealth Bio's (private) elamipretide in Barth syndrome, as we see several parallels that bode well for ALXN1840's potential approval with NDA filing expected in Q1 2026. Given both datapoints reduce the regulatory risk, we have adjusted our risk discounts lower which increases our PT to $95 from $76.
1 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 11:56 AM
BTIG has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 104.
0 · Reply
notreload_ai
notreload_ai Sep. 24 at 8:19 PM
Cantor Fitzgerald raised the firm’s price target on $MNPR to $109 from $74 and keeps an Overweight rating on the shares.
0 · Reply
Quantumup
Quantumup Sep. 24 at 8:06 PM
BTIG⬆️ $MNPR's PT to $104 from $87, reiterated at a Buy and said, $MNPR announced a published letter to the editor by leading Wilson's disease KOLs in the Journal of Hepatology detailing an updated copper balance analysis from the ph 2 copper balance study conducted by AstraZeneca ( $AZN, NR). Overall, the authors' analysis and conclusions provide an external validation of $MNPR's view that AZN's copper balance calculation was flawed, with pt by pt data showing consistent negative trends in copper balance for a majority of pts. We think the update provides a solid data point for $MNPR to discuss with the FDA as they prepare for an NDA in early 2026 and supports our PoS increase for ALXN1840, driving our new $104 PT. Reiterate our Buy rating.
0 · Reply